Skip NavigationSkip to Content
Return Return to Search Results

Human monoclonal antibodies as candidate therapeutics against emerging viruses

  1. Inventor:
    Jin, Yujia
    Lei, Cheng
    Hu, Dan
    Dimitrov, Dimiter S
    Ying, Tianlei

  2. Inventor Address

    Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China., Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA. dimitrdi@mail.nih.gov., Key Laboratory of Medical Molecular Virology of the Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China. tlying@fudan.edu.cn.,
    1. Year: 2017
    2. Date: Nov 20
    3. International Patent Classification: 2017 11 20
  2. Published Source: Frontiers of medicine
  4. Patent Type: Review
  1. Abstract:

    The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1007/s11684-017-0596-6
  3. PMID: 29159596
  4. PII : 10.1007/s11684-017-0596-6

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel